Synageva BioPharma wins EMA's marketing authorisation application validation for Sebelipase Alfa
M2 - Wed Dec 24, 5:27AM CST
Biopharmaceutical company Synageva BioPharma (NasdaqGS:GEVA) reported on Tuesday the completion of the European Medicines Agency's (EMA) Marketing Authorisation Application (MAA) for sebelipase alfa for the treatment of LAL Deficiency.
GEVA: 89.72 (-0.02)
Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA
PR Newswire - Tue Dec 23, 10:26AM CST
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced validation by the European Medicines Agency (EMA) of the Marketing Authorization Application (MAA) for sebelipase alfa for LAL Deficiency. The EMA recently granted the company's request for accelerated assessment, which has the potential to shorten the EMA's regulatory review time.
GEVA: 89.72 (-0.02)
Synageva BioPharma To Present At The 33rd Annual J.P. Morgan Healthcare Conference On Monday, January 12, 2015 at 9:00 a.m. PST
PR Newswire - Wed Dec 17, 7:00AM CST
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today its presentation at the upcoming J.P. Morgan Healthcare Conference being held in San Francisco, CA.
GEVA: 89.72 (-0.02), JPM: 62.48 (unch)
Synageva BioPharma Announces Active Investigational New Drug Application For SBC-103 For The Treatment Of Mucopolysaccharidosis IIIB
PR Newswire - Mon Dec 15, 6:00AM CST
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today that the investigational new drug (IND) application to the U.S. Food & Drug Administration (FDA) to evaluate SBC-103 as a treatment for mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) is active. The company plans to start enrolling patients with MPS IIIB in a Phase 1/2 study investigating intravenous administration of SBC-103 shortly and to report preliminary data from this study in 2015.
GEVA: 89.72 (-0.02)
Lysosomal Storage Disorder - Pipeline Review, H1 2014
M2 - Mon Dec 15, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/9z3fm9/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lysosomal Storage Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lysosomal Storage Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Sangamo BioSciences, Inc. - Neuralstem, Inc. - Amicus Therapeutics, Inc. - Cytomedix, Inc. - AngioChem Inc. - Zymenex A/S - Synageva BioPharma Corp. - Fate Therapeutics, Inc. - to-BBB technologies BV - REGiMMUNE Corporation - biOasis Technologies Inc. - ArmaGen Technologies, Inc. - Orphazyme ApS - Oxyrane Belgium NV - Ultragenyx Pharmaceutical Inc. - Minoryx Therapeutics s.l. For more information visit http://www.researchandmarkets.com/research/9z...al_storage
FATE: 4.90 (+0.23), GEVA: 89.72 (-0.02), SGMO: 14.20 (+0.14), FOLD: 7.94 (+0.06), CUR: 2.70 (+0.07)
Can the Rally in Synageva Biopharma (GEVA) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 8:38AM CST
Can the Rally in Synageva Biopharma (GEVA) Shares Continue?
GEVA: 89.72 (-0.02)
Synageva Completes BLA Submission for Sebelipase Alfa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 2:10PM CST
Synageva BioPharma Corp. (GEVA) announced the completion of the rolling submission of a biologics license application to the FDA for sebelipase alfa for LAL deficiency.
CYTK: 5.87 (+0.35), BIIB: 340.89 (+5.13), GEVA: 89.72 (-0.02), AMGN: 160.67 (+3.15)
Synageva BioPharma Completes Rolling Submission Of Biologics License Application To The FDA For Sebelipase Alfa And Submits Marketing Authorization Application To European Medicines Agency
PR Newswire - Tue Dec 02, 8:02AM CST
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today the completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for sebelipase alfa as a treatment for patients with lysosomal acid lipase deficiency (LAL Deficiency), a rare genetic disease with significant morbidity and early mortality. Included in the submission is a request for Priority Review which, if granted and the BLA is accepted for review, would shorten the FDA's anticipated regulatory review time from approximately 12 to 8 months.
GEVA: 89.72 (-0.02)
Synageva BioPharma Starts Rolling Submission Of A Biologics License Application To The FDA For Sebelipase Alfa
PR Newswire Europe - Wed Nov 26, 4:43PM CST
-- First-Ever Product Submission for LAL Deficiency
GEVA: 89.72 (-0.02)
Synageva BioPharma (GEVA): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 7:55AM CST
Synageva BioPharma (GEVA) in the Medicine-Biomedicine space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
GEVA: 89.72 (-0.02)
Synageva Up on New Phase III Data on Sebelipase Alfa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:40PM CST
Synageva BioPharma Corp. (GEVA) announced the presentation of new data from a phase III study on sebelipase alfa for LAL deficiency.
GEVA: 89.72 (-0.02), AKRX: 36.47 (+0.43), ADHD: 4.00 (+0.24), CELG: 109.60 (+3.48)
Synageva BioPharma Presents New Data From Phase 3 Study Of Sebelipase Alfa In Children And Adults With LAL Deficiency At The AASLD Meeting
PR Newswire - Mon Nov 10, 12:42PM CST
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced that data from its Phase 3, global, double-blind, placebo-controlled trial evaluating sebelipase alfa in children and adults with lysosomal acid lipase deficiency (LAL Deficiency) were presented for the first time at a medical conference during the late-breaking session of The Liver Meeting®, the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
GEVA: 89.72 (-0.02)
Synageva BioPharma Reports Third Quarter 2014 Financial Results
PR Newswire - Thu Oct 30, 3:05PM CDT
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today third quarter 2014 financial results, and provided other business updates.
GEVA: 89.72 (-0.02)
Synageva BioPharma to Present at the Nomura Biotechnology Conference
PR Newswire - Wed Oct 29, 6:05AM CDT
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today that Sanj K. Patel, President and Chief Executive Officer of Synageva, will present at the Nomura Biotechnology Conference in Boston, MA on Thursday, November 6, 2014, at 8:00 a.m. EST. The presentation will be webcast live and may be accessed from the "Webcasts & Presentations" section of the Investor Relations tab on the home page of Synageva's website at www.synageva.com.
GEVA: 89.72 (-0.02)
Synageva BioPharma Presents Sebelipase Alfa Data At The NASPGHAN Meeting
PR Newswire - Thu Oct 23, 3:05PM CDT
Synageva BioPharma Corp. (Synageva) (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today two poster presentations of sebelipase alfa data for LAL Deficiency and a satellite symposium at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) annual meeting being held October 23-26, 2014 in Atlanta, GA.
GEVA: 89.72 (-0.02)
3 Big-Volume Stocks to Trade for Breakouts
at The Street - Thu Oct 16, 8:26AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
COUP: 17.44 (+0.69), NTES: 101.31 (+0.90), GEVA: 89.72 (-0.02)
Synageva BioPharma (GEVA) Shows Strength: Stock Up 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 7:51AM CDT
Synageva BioPharma Corp. (GEVA) was a big mover last session, as its shares rose over 7% on the day.
MACK: 10.91 (+0.36), MYGN: 36.50 (+0.28), HALO: 9.34 (+0.31), GEVA: 89.72 (-0.02)
Sebelipase Alfa Phase 3 Data In Children And Adults With LAL Deficiency Selected For Oral Presentation During The Late-Breaking Session At The Liver Meeting®
PR Newswire - Wed Oct 08, 9:04AM CDT
Synageva BioPharma Corp. (Synageva) (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today that data from its Phase 3, global clinical study evaluating sebelipase alfa in children and adults with LAL Deficiency has been selected for oral presentation during the late-breaking session at The Liver Meeting®, the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), being held November 7-11 in Boston, MA.
GEVA: 89.72 (-0.02)